Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 18Terminated 7Active not recruiting 2Unknown 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1Gulf War Illness 1Breast Neoplasms 1

Interventions

pembrolizumab 438Carboplatin 321Nivolumab 293Cyclophosphamide 285Specimen Handling 257Paclitaxel 249Magnetic Resonance Spectroscopy 249Cisplatin 248Radiotherapy 218Dexamethasone 183Gemcitabine 177Biopsy 177durvalumab 169atezolizumab 149Doxorubicin 140Rituximab 138Lenalidomide 135Docetaxel 131Ipilimumab 130Bevacizumab 128Radiation 121Capecitabine 117Etoposide 116Oxaliplatin 114Fluorouracil 110Pemetrexed 109Radiosurgery 108fludarabine 106venetoclax 102Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × Mifepristone × Clear all
NCT02788981 2025-06-10

Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer

University of Chicago

Phase 2 Active not recruiting
29 enrolled 11 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04254627 2025-02-19

E/M

Nova Southeastern University

Phase 1 Active not recruiting
20 enrolled

Gulf War Illness

Data powered by HemOnc (CC BY 4.0) Colophon ⚡